Visterra Grabs $30M to Develop Influenza Treatment
October 03, 2014
Visterra has completed a $30 million Series B funding. The round was co-led by new investors Merck Research Labs Venture Fund, Vertex Venture Holdings and Temasek, and received participation from existing investors Flagship Ventures and Polaris Partners, among others. Proceeds from the funding will be used to advance the development of multiple product candidates: its lead candidate VIS410, which treats influenza strains, will enter clinical trials in 2014; and VIS513, a treatment for dengue fever, will enter trials in 2015. Visterra raised a Series A financing at the end of 2013, receiving a valuation of $65 million. In total, the company has raised over $70 million in equity since early 2008.